XORTX Therapeutics: Developing Novel Therapies That Extend Kidney Health
XORTX Therapeutics, Inc. is a drug-based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism a …
They have three programs, two of these programs are in clinical development and one is at an early stage of development, each is intended to treat rare and progressive kidney disease modulated by aberrant purine and uric acid metabolism.
XORTX Therapeutics, Inc. is a drug-based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Their focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.
They possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.
For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.
BTV Visits Atlas Salt, Graphene Manufacturing, Telescope Innovations, Nevada Organic Phosphate, Maple Gold, Intrepid Metals and Nine Mile Metals
As the resource cycle accelerates, BTV – Business Television highlights companies turning exploration, innovation and strategic growth into actionable opportunity.
